Immorta Bio Inc. has announced a patent filing for its ImmortaSome™ exosome technology, a personalized, stem cell–derived nanoparticle therapy designed to reverse chemotherapy-induced aging. Preclinical studies show promising tissue rejuvenation and reduced cellular aging. By using patient-specific blood to create “young” regenerative cells, Immorta Bio aims to enter clinical trials rapidly, targeting age-related damage and expanding to broader anti-aging applications.